GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications

ClinicalTrials.gov ID: NCT07932119

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07932119. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use among adult elective surgical patients is increasing. The exact prevalence is unclear, and the possible association with pulmonary aspiration is a major concern. This study was designed to quantify the prevalence of GLP-1 RA use and the incidence of perioperative aspiration among other 30-day pulmonary complications in adult elective surgical patients at a single institution in 2025.

Study identification

NCT ID: NCT07932119
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: University of Virginia; Other
Enrollment: 25,505 participants

Conditions and interventions

Conditions

GLP-1 Receptor Agonist Treatment

Interventions

GLP-1 Receptor Agonists Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 1, 2025 (Actual)
Primary completion: Nov 30, 2025 (Actual)
Completion: Feb 28, 2026 (Actual)
Last update posted: Nov 12, 2026

2025 – 2026

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
University of Virginia	Charlottesville	Virginia	22903	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07932119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 12, 2026